Antidepression and Prokinetic Effects of Paeoniflorin on Rats in the Forced Swimming Test via Polypharmacology

Dao-zhou Mu,1,2 Mei Xue,2 Jian-jun Xu,2 Ying Hu,3 Yi Chen,4 Ping Ren,5 and Xi Huang2

1Jining No. 1 People’s Hospital, Jining 272011, Shandong, China
2Institute of TCM-related Comorbid Depression, Nanjing University of Traditional Chinese Medicine, Nanjing 210023, China
3Hospital of Traditional Chinese Medicine of Zhongshan, Zhongshan 528400, China
4Medical College of Xiamen University, Xiamen 361005, China
5Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing 210029, China

Correspondence should be addressed to Xi Huang; tcmhuangxs9@163.com

Received 13 July 2019; Revised 14 February 2020; Accepted 29 April 2020; Published 11 July 2020

Academic Editor: Victor Kuete

Copyright © 2020 Dao-zhou Mu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Paeoniflorin, an organic compound extracted from the roots of the white peony (Paeonia lactiflora) plant, has previously been shown to exert antidepression and prokinetic effects. The traditional Chinese prescription Si-Ni-San, of which paeoniflorin is a constituent, is often used in treating depression and functional gastrointestinal disorders. The effectiveness of Si-Ni-San has been shown to be less effective in a paeoniflorin-deleted form. The present study further investigates whether paeoniflorin alone is as effective as herbal prescriptions in which the compound is a constituent, specifically any antidepressive and prokinetic effect on rats subjected to a forced swimming test (FST). The FST was used to establish the depression model. Sprague-Dawley rats were administrated with 10 mg/kg paeoniflorin by gastrogavage three times before the behavioral test and gastrointestinal motility tests, respectively. In antidepression studies, fluoxetine was used as the positive control. In order to determine the effect of paeoniflorin on the gastrointestinal movement, mosapride was used as the positive control. Plasma and hippocampus monoamine, hypothalamic-pituitary-adrenal axis, plasma brain-derived neurotrophic factor (BDNF), superoxide dismutase (SOD), methane dicarboxylic aldehyde (MDA), ghrelin, motilin, and hippocampus nitric oxide (NO) were assessed using an enzyme-linked immunosorbent assay (ELISA). Gastrointestinal (GI) motility was measured in vivo and in vitro. Rats subjected to FST showed decreased gastric emptying and intestinal transit in vivo, decreased plasma and hippocampus 5-hydroxytryptamine, norepinephrine, dopamine, ghrelin, motilin, and reduced plasma BDNF and SOD as well as increased plasma and hippocampus corticotropin-releasing hormone, adrenocorticotropic hormone, corticosterone, plasma MDA, and hippocampus NO. Paeoniflorin reversed these symptoms in a similar manner to fluoxetine and mosapride, respectively. In vitro, paeoniflorin can stimulate the jejunal contract of healthy rats dose-dependently. The results suggest that paeoniflorin can simultaneously exert antidepression and prokinetic effects via polypharmacology.

1. Introduction

The traditional Chinese prescription Si-Ni-San is often used in treating depression [1] and functional gastrointestinal disorders (FGIDs) [2]. Chaihu-Shugan-San (CSS), which is derived from Si-Ni-San, can simultaneously exert antidepression and prokinetic effects [3]. These multitarget effects of Chinese formulae may provide a more effective alternative to Western medicine in treating comorbid depression and FGIDs. Paeoniflorin is the most effective component of the two formulae. Research has shown that the paeoniflorin-deleted Si-Ni-San was significantly less effective than Si-Ni-San and paeoniflorin while paeoniflorin exhibited a similar effect to Si-Ni-San [4]. We were, therefore, very interested to test whether paeoniflorin can induce antidepressive and prokinetic effects similar to Si-Ni-San and CSS. A previous study has reported that paeoniflorin can modulate the hypothalamic-pituitary-adrenal (HPA) axis and upregulate the serotonergic and noradrenergic systems of rats exposed to chronic unpredictable stress, which may elucidate the
mechanisms of the antidepressive effect of paeoniflorin [5]. Paeoniflorin can also reduce the immobility time in forced swimming and tail suspension tests of mice and antagonize reserpine-induced ptosis, akinesia, and hypothermia, while upregulating serotonergic systems [6]. In the menopause depression model of rats, paeoniflorin can exert antidepressive effects through upregulating 5-HT1AR expression, while downregulating 5-HT2AR expression in the brains of rats [7]. There is, however, no report of both antidepressive and prokinetic effects of paeoniflorin on rats subjected to a forced swimming test (FST). Thus, in the present study, we used a 15 min FST to induce the depression-like behavioral response of rats and investigate the antidepressive and prokinetic effect of paeoniflorin on rats subjected to FST. Monoamine neurotransmitter and HPA axis were measured, while plasma brain-derived neurotrophic factor (BDNF), superoxide dismutase (SOD), methanol ducarboxylic aldehyde (MDA), and hippocampus nitric oxide (NO) were detected to investigate the mechanism of the antidepressive effect of paeoniflorin. In addition, plasma ghrelin and motilin were assessed to elucidate the mechanism of the prokinetic effect of paeoniflorin.

2. Materials and Methods

2.1. Animals. Healthy adult male Sprague-Dawley (SD) rats weighing 180–210 g (about 7 weeks old, SPF grade, offered by Shanghai Jie-si-jie Experimental Animals Co. Limited) were caged to acclimatize to their new environment for 7 days prior to experiments. All the experiments were conducted per the relevant ethical guidelines of the Experimental Animal Ethics Committee of Nanjing University of Traditional Chinese Medicine (permit number: ACU-42 (20141229)). A 12-hour light/dark cycle was maintained (lights on: 7:00–19:00; lights off: 19:00–7:00). The humidity was 55±2%, and the temperature was 21–25°C. All the rats were given free access to water and food prior to experiments. Following the drawing of experimental samples, rats were euthanized via intraperitoneal injection using a solution of 2% pentobarbital sodium 60 mg/kg weight. A total of 101 rats were used in the experiments. The experiments were carried out from September 22, 2015, to March 9, 2016. The animals’ health and behavior were monitored daily.

2.2. Drug. Paeoniflorin (purity 98%) was purchased from Nanjing Jingzhu Bio-science and Technology Co. Limited (Jiangsu, China). Fluoxetine (as a positive control in antidepressive tests) [7] and mosapride (as a positive control in prokinetic tests) [8] were bought from the Jiangsu Provincial Hospital of Traditional Chinese Medicine. All three drugs were prepared in ultrapure water at concentrations of 1 mg/ml, 2 mg/ml, and 1 mg/ml, respectively. Although fluoxetine and mosapride are not completely soluble in water, they disintegrate, forming a suspension. Before use, the suspension was shaken to fully suspend the powder in the water.

2.3. Forced Swimming Test (FST). The FST was carried out following the method of Porolf et al. [9]. Rats were forced to swim 15 min individually in a cylinder (50 cm x 25 cm) which was filled with water at a temperature of 25°C to a depth of 30 cm. The cylinder was cleaned after each test. After 24 h, the Depression Scan RH type animal despair automatic analyzer system (US, Clever) was used to record the immobility time of rats during a 5 min FST. Immobility time refers to the time during which rats stopped struggling and floated motionlessly or only tried to put their heads above water.

2.4. Open-Field Test (OFT). The OFT was performed in an open field apparatus (50 cm x 50 cm x 50 cm). The base was divided into a central area and a peripheral area by computer. Rats were placed in the center of the apparatus, one rat per open field. The TopScanHR type animal track and behavior intelligent analysis system was used to record the moving distance during 5 min in the apparatus. Ethyl alcohol was used to clean the apparatus after each test.

2.5. Antidepressive Experiment. Forty SD rats were divided randomly into four groups of ten, including a normal control (NC) group, a model (M) group, a fluoxetine (F) group, and a paeoniflorin (P) group. Apart from the NC group, rats in other groups were subjected to a single 15 min FST. Normal saline (1 ml/100 g), fluoxetine (20 mg/kg), and paeoniflorin (10 mg/kg) were orally administered to rats in the M group, F group, and P group, respectively, at three times: 24 h, 5 h, and 1 h before the behavioral test. After 24 h, OFT and 5 min forced swimming immobility time were used to evaluate the depression-like behavior of rats. All rats were deprived of food and fed with 5% glucose water only for 24 h before the behavioral test. Rats were sacrificed 30 min after the behavioral test. Blood samples were drawn from the abdominal aorta and placed in tubes with heparin which were then centrifuged at 3000 rpm for 10 min at 4°C. Supernatants were collected and stored at −80°C until assayed. Plasma monoamines and corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), corticosterone (CORT), BDNF, SOD, and MDA were assessed using enzyme-linked immunosorbent assay (ELISA). Simultaneously, rats were decollated and their hippocampi were carefully removed in order to detect monoamines, CRH, ACTH, CORT, and NO in the hippocampus using ELISA. The hippocampi were stored at −80°C prior to testing.

2.6. Measurement of GI Movement In Vivo. This test was carried out according to previous research [10, 11]. Rats, 51 in total, were divided randomly into five groups: NC group, M group, F group, P group, and mosapride group (Mo group). (The NC group contained 11 rats while each of the other groups contained 10 rats.) All rats, except those in the NC group, were subjected to a 15 min FST. Normal saline (1 ml/100 g), fluoxetine (20 mg/kg), paeoniflorin (10 mg/kg), and mosapride (10 mg/kg) were given by gavage at 24 h, 5 h, and 0.5 h prior to the gastrointestinal motility test. All rats fasted and were fed only 5% glucose water 24 h prior to the
GI motility test. 30 min after the last administration, 1 ml semiliquid nonnutrient dye (Evans blue 50 mg/ml dissolved in 0.5% methylcellulose) was orally administered to all rats. Blood samples were collected from orbit. 20 min later, all rats were anesthetized via inotraperine injection using a solution of 2% pentobarbital sodium 60 mg/kg weight. Gastric emptying (GE) and intestinal transit (IT) were measured per a previous report [12, 13]. Plasma motilin was assayed to investigate the mechanism of paeoniflorin’s effect on the gastrointestinal (GI) motility of rats in the FST.

3. Results

3.1. Behavioral Response

3.1.1. Immobility Time in 5 min Forced Swimming Test. Compared with the NC group, rats in the M group demonstrated a significant increase in immobility following 5 min FST (M group: 159.14 ± 19.66 vs NC group: 83.68 ± 9.91, p < 0.01). Fluoxetine and paeoniflorin significantly reduced the immobility time compared with the M group (F group: 104.80 ± 7.62 vs M group: 159.14 ± 19.66, p < 0.01; P group: 96.71 ± 8.27 vs M group: 159.14 ± 19.66, p < 0.01). These data are shown in Figure 1.

3.1.2. Open-Field Test (OFT). Compared with the NC group, rats in the M group exhibited significantly decreased mobility in the OFT (M group: 3719.31 ± 451.27 vs NC group: 9933.45 ± 1432.08, p < 0.01). Fluoxetine and paeoniflorin increased the moving distance remarkably compared with the M group (F group: 8628.42 ± 682.73 vs M group: 3719.31 ± 451.27, p < 0.01; P group: 8732.10 ± 655.64 vs M group: 3719.31 ± 451.27, p < 0.01) (Figure 1).

3.2. Gastrointestinal (GI) Movement

3.2.1. In Vivo Effects of Paeoniflorin on GI Movement of Rats Undergoing FST. Compared with rats in the NC group, rats in the M group showed significantly decreased GE and IT (GE: NC group 0.6451 ± 0.0558 vs M group 0.4870 ± 0.0323, p < 0.01; IT: NC group 0.695 ± 0.137 vs M group 0.371 ± 0.037, p < 0.01). Paeoniflorin can significantly promote gastrointestinal motility (GE: P group 0.6247 ± 0.0754 vs M group 0.4870 ± 0.0323, p < 0.01; IT: P group 0.565 ± 0.145 vs M group 0.371 ± 0.037, p < 0.05), in a manner similar to mosapride (GE: Mo group 0.6599 ± 0.1152 vs M group 0.4870 ± 0.0323, p < 0.05; IT: Mo group 0.677 ± 0.048 vs M group 0.371 ± 0.037, p < 0.01). Fluoxetine, however, further delayed GI movement compared with rats in the M group (GE: F group 0.4288 ± 0.0290 vs M group 0.4870 ± 0.0323, p < 0.05; IT: F group 0.308 ± 0.031 vs M group 0.371 ± 0.037, p < 0.05). These data are shown in Figure 2.

3.2.2. In Vitro Effects of Paeoniflorin, Fluoxetine, and Neostigmine on Jejunal Smooth Muscle from Healthy Rats. Compared with the preadministration of paeoniflorin, the contractile amplitude of rat jejunal smooth muscle significantly increased following the administration of paeoniflorin of varying doses, and this effect was dose-dependent: preadministration of paeoniflorin: 697.6753 ± 24.9537 vs paeoniflorin 0.5 mg/ml: 808.1867 ± 20.7491 vs paeoniflorin 1 mg/ml: 823.7092 ± 24.4624 vs paeoniflorin 2 mg/ml: 946.8912 ± 18.4724 vs paeoniflorin 4 mg/ml: 1108.7980 ± 12.0524 (Figures 3(a) and 3(b)). The higher the concentration of paeoniflorin administered, the stronger the resulting contraction.

Conversely, fluoxetine significantly reduced the contractile amplitude of rat jejunal muscle: preadministration: 1.4326 ± 0.0275 compared with after administration: 1.1001± 0.0257 (Figures 4(a) and 4(b)). When neostigmine was used to stimulate jejunal muscle contraction prior to paeoniflorin, however, the effect of neostigmine was inhibited: preadministration: 150.59 ± 8.003 vs neostigmine: 179.78 ± 13.652 vs paeoniflorin: 135.35 ± 15.430 (Figures 5(a) and 5(b)).

3.3. Effect of Paeoniflorin on Monoamines, HPA Axis, Plasma BDNF, and Hippocampus NO

3.3.1. Effect of Paeoniflorin on Monoamines in Plasma and Hippocampus. Compared to the control group, 5-hydroxytryptamine (5-HT), norepinephrine (NE), and dopamine (DA) in rats with FST decreased in both plasma and hippocampus (p < 0.01). Compared with the model group, paeoniflorin and fluoxetine can reverse these symptoms: fluoxetine group, plasma NE, and hippocampus NE, p < 0.05; others all p < 0.01. In this respect, the effect of
3.3.2. Effects of Paeoniflorin on HPA Axis. Compared with the NC group, the HPA axis of rats in the M group showed higher activity. CRH, ACTH, and CORT were significantly increased in both the plasma and hippocampus of rats in the M group ($p < 0.01$). Paeoniflorin and fluoxetine can reverse these symptoms. In this respect, the effect of fluoxetine is superior to paeoniflorin ($p < 0.01$). These data are shown in Figure 7.

3.3.3. Effect of Paeoniflorin on Plasma BDNF of Rats with FST. Compared with the NC group, rats in the M group showed decreased plasma BDNF ($p < 0.01$). Compared with the M group, paeoniflorin and fluoxetine can increase plasma BDNF of rats with FST ($p < 0.01$). In this respect, the effect of paeoniflorin is superior to that of fluoxetine ($p < 0.01$). These data are shown in Figure 8.

3.3.4. Effects of Paeoniflorin on Hippocampus NO of Rats with FST. Compared with the NC group, hippocampus NO increased significantly in rats in the M group ($p < 0.01$). Paeoniflorin and fluoxetine can decrease the hippocampus NO of rats with FST ($p < 0.01$). In this respect, the effect of paeoniflorin is inferior to that of fluoxetine ($p < 0.01$). These data are shown in Figure 8.

3.3.5. Effects of Paeoniflorin on Plasma SOD and MDA. Compared with the NC group, rats in the M group showed increased plasma MDA and decreased plasma SOD...
Figure 3: (a) Effects of paeoniflorin on the contractile amplitude of jejunal muscle from healthy rats in vitro. (b) Paeoniflorin can significantly increase the contractile amplitude of rat jejunal smooth muscle in vitro. P: paeoniflorin. **p < 0.01, compared with preadministration.

Figure 4: (a) Effects of fluoxetine on the contractile amplitude of jejunal muscle from healthy rats in vitro. (b) Fluoxetine can noticeably decrease the contractile amplitude of jejunal muscle in vitro. Flu: fluoxetine. **p < 0.01, compared with preadministration.

Figure 5: (a) Effects of paeoniflorin and neostigmine on the contractile amplitude of jejunal muscle from healthy rats in vitro. (b) Neostigmine can increase the contractile amplitude of jejunal muscle in vitro, but this change can be reversed by paeoniflorin. N: neostigmine; P: paeoniflorin. **p < 0.01, compared with preadministration; ##p < 0.01, compared with N.
Compared with the M group, paeoniflorin can elevate plasma SOD, which is superior to fluoxetine (\(p < 0.01\)), and reduce plasma MDA, which is inferior to fluoxetine (\(p < 0.01\)) (Table 1).

### 3.3.6. Effects of Paeoniflorin on Plasma Motilin of Rats with FST.
Compared with the NC group, forced swimming stress significantly decreased plasma motilin (\(p < 0.01\)). Compared with the M group, fluoxetine further reduced plasma motilin of rats subjected to FST (\(p < 0.01\)). Paeoniflorin and mosapride can increase plasma motilin of rats with FST (\(p < 0.01\)), a result not significantly different from the NC group (Figure 9).

### 4. Discussion
The results of the experiments in this study indicate that paeoniflorin can simultaneously exert antidepressant-like and prokinetic effects via polypharmacology.
We found that rats undergoing 15 min forced swimming stress showed increased immobility time following a subsequent 5 min FST and decreased mobility in the OFT. Paeoniflorin and fluoxetine can reverse these symptoms. These behavioral changes suggest that the FST can successfully induce a depression-like behavioral response of rats and evaluate the antidepressive effect of drugs. These findings are consistent with previous reports by members of our research team [3, 8].
We also found that paeoniflorin exerted antidepressive and prokinetic effects simultaneously on rats with or without FST. The antidepressive effect of paeoniflorin was similar to fluoxetine and its prokinetic effect was identical to that of mosapride. These are significant results for new drugs in treating depression, especially comorbid depression and functional gastrointestinal disorder. Compared with Western medicine, which acts on single targets, traditional Chinese prescriptions act on multitargets. This suggests that Chinese medicine may provide alternative treatments to Western medicine in complicated clinical cases. Previous reports and these results provide evidence that monosome drugs extracted from natural herbs can also have multieffects similar to their maternal formula while also having little in the way of side effects.

![Figure 7](image-url)

**Figure 7:** Effects of paeoniflorin on the HPA axis of rats subjected to FST. (a) Plasma CRH, ACTH, and CORT significantly increased in M group, while F and P can reverse these changes. (b) Hippocampus CRH, ACTH, and CORT increased markedly in the M group, while F and P can reverse these changes. Compared with the NC group, **p < 0.01. Compared with the M group, ***p < 0.01; NC, normal control; M, model; F, fluoxetine; P, paeoniflorin; HPA, hypothalamic-pituitary-adrenal; FST, forced swimming test; CRH, corticotropin-releasing hormone; ACTH, adrenocorticotropic hormone; CORT, corticosterone.

![Figure 8](image-url)

**Figure 8:** Effects of paeoniflorin on plasma BDNF and hippocampus NO of rats subjected to FST. (a) Plasma BDNF was significantly downregulated in the M group, while F and P can reverse this change. (b) Hippocampus NO obviously increased in the M group, while F and P can reverse this change. Compared with the NC group, **p < 0.01. Compared with the M group, ***p < 0.01. BDNF, brain-derived neurotrophic factor; NO, nitric oxide; FST, forced swimming test; M, model; F, fluoxetine; P, paeoniflorin.
significant difference. Compared with the NC group, p < 0.05 indicated a statistically significant difference. Compared with the NC group, **p < 0.01; compared with the M group, ##p < 0.01. SOD: superoxide dismutase; MDA: methane dicarboxylic aldehyde; FST: forced swimming test; NC: normal control; M: model; F: fluoxetine; P: paeoniflorin. 

Table 1: Effects of paeoniflorin on plasma SOD and MDA of rats with FST (± SD).

| Group   | n | SOD (U/ml)  | MDA (nmol/l) |
|---------|---|-------------|--------------|
| NC group| 9 | 104.50 ± 7.57 | 10 | 5.29 ± 0.75 |
| M group | 10| 47.93 ± 8.98** | 10 | 11.11 ± 0.78** |
| F group | 9 | 63.21 ± 8.17## | 9  | 6.38 ± 0.59## |
| P group | 10| 74.33 ± 7.67## | 10 | 7.48 ± 0.75## |

Data are shown as mean ± standard deviation (± SD), and one-way analysis of variance (ANOVA) followed by a least significant difference (LSD) test was used to evaluate the data. p < 0.05 indicated a statistically significant difference. Compared with the NC group, **p < 0.01; compared with the M group, ##p < 0.01.

Motilin, named because of its stimulation of gastric motility, is a polypeptide hormone secreted by M cells in the proximal small intestine. It is a 22-amino acid protein. Motilin plays a role in the phase III stage of the migrating motor complex (MMC). Phase III may enable the stomach and intestine to eliminate the undigested content and can prevent bacteria from overgrowing in the proximal intestine. It may be related to the sense of hunger [22]. Low concentrations of motilin can stimulate the function of neurons in the upper intestine, while higher levels of motilin can directly promote the gut muscle's contraction [23]. In this study, we found that plasma motilin decreased in rats with FST, and paeoniflorin can reverse this change. Conversely, fluoxetine further decreased plasma motilin. M these phenomena may explain the mechanism of the prokinetic effect of paeoniflorin.
The experiment which measured the effect of paeoniflorin on GI motility in vitro demonstrated that paeoniflorin can directly contract the jejunal muscle dose-dependently. This method excluded the factors in the internal environment of the body such as drug metabolism and other endocrine factors which may affect the results. We were, therefore, able to observe the direct action on jejunal muscles of paeoniflorin at varying doses.

In summary, paeoniflorin can attenuate the depression-like behavior of rats subjected to 15 min forced swimming stress (Figure 1). This may be due to its upregulation of plasma and hippocampus monoamines (Figure 6), plasma BDNF (Figure 8), and SOD (Table 1) as well as its downregulation of plasma MDA (Table 1), hippocampus NO (Figure 8), and activity of HPA axis (Figure 7). The antidepressive effects of paeoniflorin, as reported by Huang et al., may be due to its downregulation of HPA [7]. Moreover, paeoniflorin can promote GI motility both in vivo and in vitro, which may be related to its upregulation of plasma motilin (Figures 2–5 and 9). Previous findings have shown that paeoniflorin was the main constituent of Bai-Shao, which played an indispensable role in the antidepressant effect of CSS [24]. Previous studies have also demonstrated that CSS may cause antidepressive effects via regulation of the hippocampal BDNF-TrkB-ERK/Akt signaling pathway [25], while our research has shown that paeoniflorin can exert antidepressive and prokinetic effects similar to those found by CSS [3].

In future studies, we aim to investigate the antidepression and prokinetic effects of paeoniflorin on rats exposed to chronic unpredictable stress.

Data Availability

The statistical data used to support the findings of this study are included within the article and are available from the corresponding author upon request.

Conflicts of Interest

The authors confirm that there are no conflicts of interest associated with this publication.

Acknowledgments

This work was supported by the National Natural Science Fund (nos. 81072967 and 81573797) and Doctoral Research Startup Foundation of Jining No. 1 People's Hospital. It was also supported by funding from the Priority Academic Program Development of Jiangsu Higher Education Institutions (integration of Chinese and Western medicine) and by the high-level talents of Nanjing University of Chinese Medicine.

References

[1] Y. Li, Y. Sun, X. Ma et al., “Effects of Sini San used alone and in combination with fluoxetine on central and peripheral 5-HT levels in a rat model of depression,” Journal of Traditional Chinese Medicine, vol. 33, no. 5, pp. 674–681, 2013.

[2] S. P. Yu, H. Ye, N. L. Ha, S. Q. Ding, and G. Chen, “Effect of modified Sinisan on anorectal manometry of the constipation predominant type of Irritable Bowel Syndrome,” Chinese Journal of Integrative Medicine, vol. 11, no. 1, pp. 27–30, 2005.

[3] Y.-j. Zhang, X. Huang, Y. Wang et al., “Ferulic acid-induced anti-depression and prokinetics similar to Chaihu-Shugan-San via polypharmacology,” Brain Research Bulletin, vol. 86, no. 3-4, pp. 222–228, 2011.

[4] Y. Sun, Y. Dong, H. J. Jiang et al., “Dissection of the role of paeoniflorin in the traditional Chinese medicinal formula Si-Ni-San against contact dermatitis in mice,” Life Sciences, vol. 84, no. 11–12, pp. 337–344, 2009.

[5] F.-M. Qiu, X.-M. Zhong, Q.-Q. Mao, and Z. Huang, “Antidepressant-like effects of paeoniflorin on the behavioural, biochemical, and neurochemical patterns of rats exposed to chronic unpredictable stress,” Neuroscience Letters, vol. 541, pp. 209–213, 2013.

[6] F. Qiu, X. Zhong, Q. Mao, and Z. Huang, “The antidepressant-like effects of paeoniflorin in mouse models,” Experimental and Therapeutic Medicine, vol. 5, no. 4, pp. 1113–1116, 2013.

[7] H. Huang, J. Zhao, L. Jiang et al., “Paeoniflorin improves menopause depression in ovariecotomized rats under chronic unpredictable mild stress,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 4, pp. 5103–5111, 2015.

[8] Y. Xie, X. Huang, S.-Y. Hu et al., “Meranzin hydrate exhibits anti-depressive and prokinetic-like effects through regulation of the shared alpha 2-adrenoceptor in the brain-gut axis of rats in the forced swimming test,” Neuropharmacology, vol. 67, pp. 318–325, 2013.

[9] R. D. Porsolt, M. Le Pichon, and M. Jalfre, “Depression: a new animal model sensitive to antidepressant treatments,” Nature, vol. 266, no. 5604, pp. 730–732, 1977.

[10] B. Y. De Winter, G. E. Boeckxstaens, J. G. De Man et al., “Effect of different prokinetic agents and a novel enterokinetic agent on postoperative ileus in rats,” Gut, vol. 45, no. 5, pp. 713–718, 1999.

[11] B. Y. De Winter, A. J. Bredenoord, J. G. De Man, T. G. Moreels, A. G. Herman, and P. A. Pelckmans, “Effect of inhibition of inducible nitric oxide synthase and guanylyl cyclase on endotoxin-induced delay in gastric emptying and intestinal transit in mice,” Shock, vol. 18, no. 2, pp. 125–131, 2002.

[12] J. De Winter and J. Wagemans, “Contour-based object identification and segmentation: stimuli, norms and data, and software tools,” Behavior Research Methods, Instruments, & Computers, vol. 36, no. 4, pp. 604–624, 2004.

[13] S. Lange, D. S. Delbro, and E. Jennische, “Evans blue permeation of intestinal mucosa in the rat,” Scandinavian Journal of Gastroenterology, vol. 29, no. 1, pp. 38–46, 1994.

[14] G. Sözeri-Varma, Y. Enli, T. Toker-Uğurlu, H. Alaçam, and N. Kalkan-Öğuzhanoglu, “Decreased serum BDNF levels in major depressive patients,” Neurology, Psychiatry and Brain Research, vol. 17, no. 4, pp. 84–88, 2011.

[15] M. Poljakova, K. Stuke, K. Schuemburg, K. Mueller, P. Schoenknecht, and M. L. Schroeter, “BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis,” Journal of Affective Disorders, vol. 174, pp. 432–440, 2015.

[16] O. Aydemir, A. Deveci, and F. Taneli, “The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 29, no. 2, pp. 261–265, 2005.
[17] S.-F. Gao, Y.-R. Lu, L.-G. Shi et al., “Nitric oxide synthase and nitric oxide alterations in chronically stressed rats: a model for nitric oxide in major depressive disorder,” Psychoneuroendocrinology, vol. 47, pp. 136–140, 2014.

[18] H. Herken, A. Gurel, S. Selekt et al., “Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment,” Archives of Medical Research, vol. 38, no. 2, pp. 247–252, 2007.

[19] L. A. Saleh, M. Hamza, N. H. El Gayar, A. A. Abd El-Samad, E. A. Nasr, and S. I. Masoud, “Ibuprofen suppresses depressive like behavior induced by BCG inoculation in mice: role of nitric oxide and prostaglandin,” Pharmacology Biochemistry and Behavior, vol. 125, pp. 29–39, 2014.

[20] S. Jiménez-Fernández, M. Gurpegui, F. Díaz-Atienza, L. Pérez-Costillas, M. Gerstenberg, and C. U. Correll, "Oxidative stress and antioxidant parameters in patients with major depressive disorder compared to healthy controls before and after antidepressant treatment," The Journal of Clinical Psychiatry, vol. 76, no. 12, pp. 1658–1667, 2015.

[21] L. Shu-Qi, P. Jing-Bo, Z. Zhong-Mei, S. Zhi-Heng, and Y. Chang-Yuan, "In Vitro and in vivo antioxidant effects and the possible relationship between the anti-depression efficacy of Traditional Chinese Medicine formulation Chaihu Shugan San," Chinese Journal of Natural Medicines, vol. 8, no. 5, pp. 353–361, 2010.

[22] E. Husebye, "The patterns of small bowel motility: physiology and implications in organic disease and functional disorders," Neurogastroenterology & Motility, vol. 11, no. 3, pp. 141–161, 1999.

[23] G. J. Sanger, “Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases,” Drug Discovery Today, vol. 13, no. 5-6, pp. 234–239, 2008.

[24] X. Chang, H. Jia, C. Zhou et al., "Role of Bai-Shao towards the antidepressant effect of Chaihu-Shu-Gan-San using metabonomics integrated with chemical fingerprinting,” Journal of Chromatography B, vol. 1006, pp. 16–29, 2013.

[25] X.-Q. Chen, C.-F. Li, S.-J. Chen et al., “The antidepressant-like effects of Chaihu Shugan San: dependent on the hippocampal BDNF-TrkB-ERK/Akt signaling activation in perimenopausal depression-like rats,” Biomedicine & Pharmacotherapy, vol. 105, pp. 45–52, 2018.